Thymalfasin for the treatment of chronic hepatitis C infection

Annals of the New York Academy of Sciences

Volumn 1112, Issue , 2007, Pages 357-367

  Rustgi, Vinod K ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

HCV; HCV nonresponders; Thymalfasin; Thymosin alpha 1; Zadaxin

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; THYMOSIN ALPHA1;

ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; BEHAVIOR DISORDER; BONE MARROW TOXICITY; BRAIN TOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; DEPRESSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS C; HISPANIC; HUMAN; INFERTILITY; INSOMNIA; KIDNEY INJURY; LIVER INJURY; LOW DRUG DOSE; MALAISE; MONOTHERAPY; MYALGIA; NAUSEA; NAUSEA AND VOMITING; PHARYNGITIS; PRURITUS; RASH; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; THYROID DISEASE; TREATMENT RESPONSE; VIRUS INFECTION; VIRUS LOAD; VOMITING; WEIGHT REDUCTION;

HEPATITIS C VIRUS;

EID: 35348980090     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1415.034     Document Type: Conference Paper

References (17)

1. FRIED, M.W., M.L. SHIFFMAN, K.R. REDDY, et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347: 975-982.
2. GISH, R.G. 2004. Treating hepatitis C: the state of the art. Gastroenterol. Clin. North Am. 33(1 Suppl): S1-S9.
3. MOSCARELLA, S., G. BUZZELLI, R.G. ROMANELLI, et al. 1998. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results. Liver 18: 366-369.
4. HEPBURN, M.J., L.M. HEPBURN, N.S. CANTU, et al. 2004. Differences in treatment outcome for hepatitis C among ethnic groups. Am. J. Med. 117: 163-168.
5. DANTZLER, T.E. & E.J. LAWITZ. 2003. Treatment of chronic hepatitis C in nonresponders to previous therapy. Curr. Gastroenterol. Rep. 5: 78-85.
6. SHIFFMAN, M.L., C.M. HOFFMAN, M.J. CONTOS, et al. 1999. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 117: 1164-1172.
7. SHERMAN, K.E., M. SJOGREN, R.L. CREAGER, et al. 1998. Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 27: 1128-1135.
8. POO, J.L., F. SANCHEZ-AVILA, D. KERSHENOBICH, et al. 2004. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study. J. Gastroenterol. Hepatol. 19: S79-S81.
9. POCKROS, P.J. 2002. Developments in the treatment of chronic hepatitis C. Exp. Opin. Investig. Drugs 11: 515-528.
10. MCHUTCHISON, JG, S.C. GORDON, E.R. SCHIFF, et al. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339: 1485-1492.
11. 2003. Roferon-A® Package Insert. Hoffmann-LaRoche, NJ, USA.
12. DUSHEIKO, G., J. MAIN, H. THOMAS, et al. 1996. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J. Hepatol. 25: 591-598.
13. MANNS, M.P., J.G. MCHUTCHISON, S.C. GORDON, et al. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
14. RASI, G., D. DIVIRGILIO, M.G. MUTCHNICK, et al. 1996. Combination thymosin α1 and lymphoblastoid interferon treatment in chronic hepatitis C. Gut 39: 679-683.
15. ANDREONE, P., C. CURSARO, A. GRAMENZI, et al. 1996. A double-blind, placebo-controlled pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Liver 16: 207-210.
16. RUSTGI, V. 2004. Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment. J. Gastroenterol. Hepatol. 19: S76-S78.
17. POO, J.L., F. SANCHEZ-AVILA, D. KERSHENOBICH, et al. 2004. A pilot trial of thymalfasin (thymosin alpha-1) in combination with peginterferon alpha-2a (PEG-IFN2a) and ribavirin in HCV non-responders: 48-week (end of therapy) results. Hepatology 40(Suppl 1): 91A.